High-dose chemotherapy with autologous SCT has become standard of care for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). To improve safety and efficacy of this treatment, new conditioning regimens are being developed. We retrospectively reviewed clinical data of patients with relapsed NHL treated at our institution with i.v. BU and CY (BU/CY) as conditioning regimen for autologous SCT between January 2000 and April 2005. We identified 43 patients (24 men, 19 women, median age 50) with diffuse large B-cell lymphoma (n ¼ 28), follicular lymphoma (n ¼ 8), mantle cell lymphoma (n ¼ 4) and peripheral T-cell lymphoma (n ¼ 3). Following salvage chemotherapy, there were 26 complete responses, 13 partial responses and 4 stable diseases. Median time to neutrophil and platelet recovery was 11 and 13.5 days, respectively. Treatmentrelated toxicities included nausea/vomiting, diarrhea and mucositis. The 100-day mortality was 9%: sepsis (n ¼ 1), pneumonia (n ¼ 1) and hepatic veno-occlusive disease (n ¼ 2). Twenty-one patients were followed until death and twenty-one surviving patients were followed for a median of 29 months (range 0.4-76). Three-year estimates of event-free survival, progression-free survival and overall survival were 35, 39 and 43%, respectively. We conclude that i.v. BU/CY is a safe and effective conditioning regimen for autologous SCT in relapsed NHL.
Introduction
Based on the results of the PARMA group trial, high-dose chemotherapy followed by autologous SCT has become the standard of care for patients with relapsed, chemosensitive aggressive non-Hodgkin's lymphoma (NHL).
1,2 Multiple chemotherapy-based conditioning regimens including CBV, BEAM and BEAC have been developed in recent years in an effort to combine high antitumor activity with acceptable toxicity to normal tissues. 3 However, treatment-related mortality and relapse of the residual primary disease continue to be major limitations to treatment success. To date, there is no evidence for a superior high-dose conditioning regimen in the treatment of relapsed/refractory NHL.
The combination of BU and CY as a pretransplant conditioning regimen has been used for both allogeneic and autologous SCT in patients with hematologic and nonhematologic malignancies. 4, 5 Although high-dose oral BU has proven to be an effective component in this combination, the oral route of administration is complicated by erratic absorption and thus highly variable bioavailability, leading to unpredictable systemic exposure and toxicity. Since the development of a parenteral formulation of BU with 100% bioavailability, several studies have confirmed favorable safety, efficacy and pharmacokinetic profiles of various dosing and scheduling schemes using i.v. BU. [6] [7] [8] In a previous report from our institution, Fernandez et al. 9 evaluated twice-daily or once-daily dosing schedules for i.v. BU in combination with CY, demonstrating reproducible pharmacokinetics and clinical safety. We are now reporting our experience using i.v. BU/CY dosing regimens in 43 patients undergoing autologous SCT for relapsed NHL.
Patients and methods

Study design and patients
After obtaining IRB approval, we retrospectively reviewed the clinical data of 43 consecutive patients with relapsed NHL who had been treated with i.v. BU and CY as conditioning regimen for autologous SCT between January 2000 and April 2005. Before treatment with chemotherapy, pathology was confirmed in all patients by a hematopathologist at our institution. To be considered eligible for SCT, patients were required to demonstrate adequate ECOG performance status, cardiac, pulmonary, hepatic and renal function, as well as absence of acute bacterial or viral infections.
Status at transplantation was defined by response to salvage chemotherapy based on computer tomography imaging, according to standardized response criteria, 10 and categorized as CR, CR unconfirmed (CRu), partial response (PR) or stable disease (SD). CR was defined as complete disappearance of all evidence of lymphoma. PR was defined as more than 50% decrease in all measurable diseases.
In addition to demographic data, information on previous chemotherapy regimens, duration of initial response, disease stage at relapse, remission status before transplant, time to neutrophil and platelet engraftment, treatment complications, disease and vital status at follow-up and causes of death were extracted from the patients' medical records. We determined treatment-related morbidity and mortality, EFS, PFS, disease-free survival (DFS) and OS.
Autologous SCT procedure and patient follow-up All patients underwent transplantation following salvage chemotherapy, using peripheral blood hematopoietic stem cells mobilized with G-CSF and collected through a largebore central venous catheter. Subcutaneous (s.c.) G-CSF was administered at a dose of 10 mg/kg/d for 10 days. On the eleventh day, apheresis was initiated and continued daily until X2 Â 10 6 /kg CD34 þ cells were collected and cryopreserved. As pretransplant conditioning regimen, BU was administered at a total dose of 3.2 mg/kg i.v. on days À7 to À4 (in two or four divided doses). BU pharmacokinetic levels were not drawn; therefore, no dose adjustments were made in these patients. Six to twelve hours after the last BU dose, CY 120 mg/kg was given i.v. on days À3 and À2. All patients received seizure prophylaxis with phenytoin from day À8 to day À3; doses were adjusted to a therapeutic level of 10-20 mg/ml. After a day of rest, autologous PBSC were infused on day 0, followed by G-CSF at 5 mg/kg s.c. daily starting on the same day and continued until the ANC was above 1.5 Â 10 3 /mcl. Standard support measures in the post transplantation period included antibiotics and blood transfusions, according to our Bone Marrow Transplantation Unit policies. During follow-up, disease response was assessed by computer tomography imaging in 3-month intervals for the first 2 years, 6-month intervals for the following 3 years and then annually after transplantation.
Statistical analysis
Descriptive statistics are presented for patient characteristics at the time of transplantation as counts and percentages for categorical variables and mean (±s.d.) with median (range) for continuous variables. KaplanMeier estimates were obtained for EFS, PFS, DFS and OS. EFS was defined as the time period between transplantation and the occurrence of a serious morbidity (that is, lifethreatening, requiring inpatient hospitalization or prolongation of existing hospitalization, resulting in death, persistent or significant disability/incapacity), disease relapse, disease progression or death from any cause. PFS was defined as the time from transplantation to disease relapse, progressive disease or death (treatment-or disease related). OS was defined as the time from transplantation to date of last follow-up or death from any cause. DFS was computed in the subset of 27 patients who were either in CR or CRu at the time of transplantation. Disease-free status was defined as either no evidence of disease at last contact or death from causes unrelated to treatment or disease. Patients who did not experience the respective event were censored at the date of last contact. The logrank test was used to test the effect of response status at the time of transplantation on EFS. Table 1 presents descriptive statistics for demographics and patient characteristics before transplantation. A total of 43 consecutive patients, 24 (56%) men and 19 (44%) women, with a median age of 50 (range 20-68) were identified. The distribution by histologic type was as follows: 28 (65%) diffuse large B-cell lymphoma (DLBCL), 8 (19%) follicular lymphoma (6 grade I, 1 grade II, 1 grade III), 4 (9%) mantle cell lymphoma, and 3 (7%) peripheral T-cell lymphoma. Median age at transplantation was 50 (range 20-68 years). Before transplantation, patients had received a variety of chemotherapy regimen, ranging from 2 to 5 (median 2). Duration of response to initial treatment was less than 12 months in 23 (56%) patients and greater than 12 months in 18 (44%) patients. Disease stage at relapse could not be ascertained from the medical records in 2 cases; of the remaining 41 patients, 27 (69%) presented with advanced disease (stage III or IV, whereas 12 (31%) had localized disease (stage I or II). At the time of transplantation, 26 patients (60%) had attained a CR or CRu to salvage chemotherapy, 13 (30%) had achieved a PR and 4 (9%) had SD by standardized response criteria.
Results
Patient characteristics
Treatment-related morbidity and mortality Treatment-related toxicities (Table 2 ) included nausea/ vomiting in 34 (79%), diarrhea in 20 (47%) and mucositis in 26 (60%) patients, which were mild in the majority of cases. Grades II and III mucositis occurred in 4 (9%) and 2 (5%) patients, respectively. There were no cases of grade IV mucositis. Neutropenic fever occurred in 35 (81%) patients. The majority of these patients (22; 63%) had negative results on blood cultures, 12 (34%) had evidence of grampositive bacteremia, mainly Staphylococcus epidermidis. One patient developed catheter-related sepsis due to coagulase-negative Staphylococcus organism. No cases of gram-negative bacteremia were found on culture. Three patients (7%) developed colitis due to Clostridium difficile infection. Skin rash was observed in seven patients (16%) during administration of the preparatory regimen. One patient experienced a grand mal seizure after prophylaxis with phenytoin had been discontinued due to occurrence of a generalized rash. Two patients (5%) developed atrial fibrillation, which was controlled medically. One patient developed severe pulmonary toxicity post transplantation requiring intubation and mechanical ventilation but recovered with supportive care. Sputum culture and bronchoscopy results were negative. Grades I and II elevation of hepatic transaminases and bilirubin was observed in 29 (67%) and 11 (26%) patients, respectively. Four patients experienced grades III or IV hepatotoxicity, two of whom developed fatal veno-occlusive disease (VOD). The other two patients did not develop clinical features of VOD; one died of septic shock with hepatic and multiorgan failure, and one had an otherwise uncomplicated hospital course with complete recovery of liver function. In all other patients, bilirubin and transaminase elevations were mild and transient after transplantation. One patient with chronic hepatitis B was treated with lamivudine throughout the pre-and post transplantation period, without any hepatic complications.
Four patients (9%) died within 100 days of transplantation: one patient developed sepsis from coagulase-negative staphylococci with multiorgan failure and died on day þ 12. Another patient died of presumed fungal pneumonia despite maximum ventilatory support on day þ 35. Two patients, aged 56 and 68, developed hepatic VOD with subsequent multiorgan failure and died on days þ 25 and þ 55, respectively. Both patients who died from VOD had received routine antifungal prophylaxis with itraconazole, and one patient had been heavily pretreated with two different salvage regimens before transplantation.
Patient outcome and survival
All patients-with the exception of one patient who died on day þ 12 of septic complications-had successful stem cell engraftment with a median time to neutrophil recovery of 11 days (range 7-18 days). Platelet recovery was seen after a median of 13.5 days (range 9-64 days), with delayed recovery (430 days) in seven patients. One patient was diagnosed with autoimmune thrombocytopenia after transplantation and responded to high dose steroids. Three patients were lost to follow-up after discharge from the Bone Marrow Transplantation Unit.
Overall survival
Of the patients, 22 had died after a median follow-up of 10 months (range: 12 days to 3.6 years)-15 from recurrent/ progressive lymphoma, 4 due to treatment-related side effects, 2 from unrelated causes and one from an unknown cause. The remaining 21 patients who were alive were followed for a median of 29 months (range: 0.4-76 months). Kaplan-Meier estimates of the proportion of NHL patients surviving to 1, 2 and 3 years were 68% (95% CI: 51-80%), 53% (95% CI: 36-68%) and 43% (95% CI: 26-58%), respectively ( Figure 1 ). Median overall survival time was 27.5 months (95% CI: 13.2-43.3).
Event-free survival
Of the patients, 25 experienced an event after a median follow-up of 6 months (range: 0.4-45 months). The 18 patients who remained event-free were followed for a median of 29 months (range: 0.4-76 months). KaplanMeier estimates of the proportion of NHL patients who remained event-free at 1, 2 and 3 years were 58% (95% CI: 42-72%), 49% (95% CI: 33-64%) and 35% (95% CI: 20-51%), respectively. Median event-free time was 22.6 months (95% CI: 6.6-33.2). A response status of either CR or CRu at the time of transplantation was associated with improved EFS (P ¼ 0.043, log-rank test). Three-year EFS in the CR/CRu group (26 patients) was 48% (95% CI: 25-68%) as compared with 21% (95% CI: 5-43%) for PR/SD patients. Median event-free time was 25.5 months (95% CI: 11-25.5) and 8.5 months (95% CI: 2.4-18.2), respectively (Figure 2 ).
Progression-free survival
Of the patients, 23 had disease progression after a median follow-up of 6 months (range: 0.4-3.7 years). The 20 patients who remained progression-free were followed for a median of 2.3 years (range: 0.4-6.4 years). Kaplan-Meier estimates of the proportion of NHL patients who remained progression-free at 1, 2 and 3 years were 60% (95% CI: 43-73%), 54% (95% CI: 37-68%) and 39% (95% CI: 22-55%), respectively ( Figure 3 ). Median progression-free time was 25 months (range 8.5-44.8). Disease-free survival DFS was computed in the subset of 26 patients who were either CR or CRu at the time of transplantation (Figure 4) . Eleven patients had evidence of disease after a median follow-up of 6.6 months (range: 0.8-26 months). The 15 patients who remained disease-free were followed for a median of 28 months (0.4-71 months). Kaplan-Meier estimates of proportion of CR/CRu NHL patients who remained disease-free at 1, 2 and 3 years were 70% (95% CI: 48-85%), 60% (95% CI: 37-77%) and 48% (95% CI: 25-68%), respectively.
Subgroup of DLBCL
Of the patients, 28 with DLBCL were included in our study, accounting for the majority (65%) of patients treated with the i.v. BU/CY conditioning regimen. In this subgroup of patients, median age at transplantation was 51 (range 26-68 years). Before transplantation, patients had received between 2 and 5 chemotherapy regimens (median 2). Duration of response to initial treatment was less than 12 months in 16 (57%) patients and greater than 12 months in 12 (43%) patients. Disease stage at relapse could not be ascertained from the medical records in one case; of the remaining 27 patients, 15 (56%) presented with advanced disease (stages III or IV, whereas 12 (44%) had localized disease (stages I or II). At the time of transplantation, 16 patients (57%) had attained a CR or CRu to salvage chemotherapy, 8 (29%) had achieved a PR, and 4 (14%) had SD by standardized response criteria. We determined OS, EFS, PFS and DFS in this subgroup of patients.
DLBCL overall survival
Of the patients, 17 had died after a median follow-up of 8 months (range: 1.2-28)-13 from recurrent/progressive lymphoma, 2 due to treatment-related side effects, 1 from unrelated cause and 1 from unknown cause. The other 11 patients who were alive were followed for a median of 37 months (range: 0.5-71). Kaplan-Meier estimates of proportion of DLBCL patients surviving to 1, 2, and 3 years were 59%, (95% CI: 39-75%), 43% (95% CI: 24-61%), and 34% (95% CI: 17-53%), respectively ( Figure 5 ). Median overall survival time was 15.9 months (95% CI: 8.1-28.1).
DLBCL event-free survival
Of the 28 patients with relapsed DLBCL, 18 experienced an event after a median follow-up of 3.5 months (range: 0.6-45). The 10 patients who remained event-free were followed for a median of 36 months (range: 0.5-71). Kaplan-Meier estimates of the proportion of DLBCL patients who remained event-free at 1, 2, and 3 years were 48% (95% CI: 29-65%), 40% (95% CI: 21-58%) and 35% (95% CI: 18-53%), respectively ( Figure 6 ). Median eventfree time was 9.1 months (95% CI: 2.6-25.5). A response status of either CR or CRu at the time of transplantation was associated with improved EFS (P ¼ 0.015, log-rank test). One-year EFS in the CR/CRu group (16 patients) was 67% (95% CI: 38-85%) as compared with 25% for the PR/ SD group (95% CI: 6-50%). Median event-free time was not reached in the CR/CRu group, whereas the median was 4.3 months in the PR/SD group (95% CI: 2.1-9.1).
DLBCL progression-free survival
Of 28 patients with relapsed DLBCL, 16 had disease progression after a median follow-up of 3 months (range 0.6-45). The 12 patients who remained progression-free were followed for a median of 31 months (range: 0.5-71). Kaplan-Meier estimates of the proportion of DLBCL patients who remained progression-free at 1, 2 and 3 years were 51% (95% CI: 31-68%), 46% (95% CI: 26-64%) and 41% (95% CI: 21-59%), respectively ( Figure 7) . Median progression-free time was 22.6 months (range: 2.6-44.8).
Disease-free survival DFS was computed in the subset of 16 patients who were either CR or CRu at the time of transplantation (Figure 8) . Seven patients had evidence of disease after a median follow-up of 3 months (range: 1.2-26). The nine patients who remained disease-free were followed for a median of 37 months (range: 0.5-71). Kaplan-Meier estimates of proportion of DLBCL patients with CR/CRu status at transplantation who remained disease-free at 1, 2 and 3 years were 67% (95% CI: 38-85%), 59% (95% CI: 31-79%) and 52% (95% CI: 25-74%), respectively.
Discussion
Despite the proven benefit of high-dose chemotherapy and autologous SCT in relapsed NHL, there is no clear evidence of a superior conditioning regimen. Due to the lack of randomized trials, the heterogeneity of disease, variability of patient characteristics and remission status, differences in outcome are difficult to compare. However, some major causes of both early and long-term mortality after transplantation are due to toxicity of the conditioning regimen, and reduction of treatment-related toxicity may significantly improve patient outcome.
Since the early 1980s, most conditioning regimens for the treatment of lymphoma have included a combination of CY (±etoposide) with either TBI or BCNU, resulting in excellent long-term survival. However, patients who have previously received radiation therapy as part of the initial treatment for their lymphoma may not be eligible for TBI because of tissue dose limitations. Moreover, in recent studies, a significant proportion (22%) of patients treated with TBI experienced grades III to IV toxicities, and treatment-related mortality rates of up to 12% have been reported. 11 Toxicities of BCNU-containing regimens, such as BEAM and BEAC, are concerning for a high incidence of interstitial pneumonitis. 12, 13 Furthermore, results from the Bone Marrow Transplant Survivor Study have shown a significantly increased rate of non-relapse related mortality after autologous SCT for hematologic malignancies with BCNU-based regimens that was not observed with BU-or TBI-based regimens. Few series using BU/CY as the conditioning regimen for autologous SCT in patients with relapsed NHL have been reported. De Magalhaes-Silverman et al. reported 2-year OS and EFS of 50 and 33%, respectively, with a regimen including oral BU and CY in 20 patients with Hodgkin's lymphoma and NHL. Regimen-related toxicities were mild and no treatment-related mortality was observed. However, there was a 15% incidence of VOD of the liver with this approach. 5 A combination regimen consisting of oral BU with CY and etoposide was reported by Kroger et al. Herein, 16 patients with NHL and 4 patients with Hodgkin's lymphoma underwent autologous SCT. OS and DFS after a median follow-up of 50 months were 55 and 50%, respectively. Regimen-related toxicity included mucositis, dermatitis and hepatic toxicity. One patient died of VOD. 15 Another study using the same conditioning regimen was published by Hanel et al. who treated 10 patients with Hodgkin's lymphoma and 43 with NHL. The 3-year OS and EFS were 43 and 31%, respectively. Regimen-related toxicity included mucositis and hepatic VOD, with a treatment-related mortality of 3.8%. 16 In a recently published study by Aggarwal et al., comparing i.v. to oral BU in combination with CY and etoposide in 49 patients with intermediate-and high-risk NHL, significantly improved 5-year OS (58 vs 28%) and PFS (50 vs 17%) were observed with i.v. administration of BU and pharmacokinetic-directed dosing. Treatment-related mortality was 28% for oral BU vs 3% for i.v. formulation. In particular, there were no occurrences of hepatic VOD with use of i.v. BU. 17 In our series using i.v. BU and CY in 43 patients with NHL, 3-year OS and EFS were 43 and 35%, respectively. These results are comparable to those of other studies in which patients with similar characteristics were enrolled. The 3-year DFS for the subgroup of patients in CR or CRu at the time of transplantation was 48% for all histologies and 52% for the DLBCL subgroup. In a large study of 452 patients with DLBCL from the Spanish registry (GEL-TAMO), who underwent autologous SCT after a variety of conditioning regimens (BEAM, BEAC, CBV and CY þ TBI), 5-year OS and DFS of 53 and 43% were reported. However, median age in that patient population was younger (42 years) and a significant proportion of patients (32%) were transplanted in first CR. 18 Our patient population included a relatively high proportion of patients with unfavorable prognostic features, including mantle cell type, short duration of initial response to chemotherapy, stage III or IV disease at relapse, treatment with three or more chemotherapy regimens before transplantation and response status of less than CR or CRu at the time of transplantation. We also included four patients with SD at the time of transplantation. These patients had achieved a response radiographically, but did not meet criteria for PR. All patients had successful hematologic engraftment. Regimen-related toxicities were similar to those reported in the literature. However, our transplant-related mortality rate (9%) is slightly higher than the reported average early treatmentrelated mortality of 5% or less. 19, 20 On the other hand, we have not observed any cases of secondary myelodysplasia (MDS) or treatment-related AML during a median followup period of 29 months after transplantation. Some studies have shown a relatively high incidence of secondary MDS as a late complication of autologous SCT with relative risk as high as to 18% at 6 years. 21 The occurrence of hepatic VOD remains the most serious and potentially life-threatening side effect of this regimen. Careful patient selection as well as pharmacokineticdirected dosing of i.v. BU may aid in reducing the risk of VOD.
In summary, the combination of i.v. BU and CY is a safe and effective autologous SCT conditioning regimen for patients with relapsed, chemosensitive NHL. There may be clinical scenarios in which this approach may present a preferable alternative to other published conditioning regimens. Due to excellent penetration of the blood-brain barrier, the combination of BU and CY-although not tested in this study-may be a better option for patients with central nervous system lymphoma. 22 It may also be a more desirable approach than CBV and BEAM for patients who have previously failed an etoposide containing salvage regimen. Overall, our results are comparable to those of other published regimens. Further investigation using i.v. BU in combination with CY or with other novel cytotoxic agents as well as incorporation of immunologic approaches using monoclonal antibodies is warranted.
